Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6481 to 6495 of 7690 results

  1. Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

    In development [GID-TA10592] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

    In development [GID-TA10483] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Ex utero intrapartum therapy for fetal obstruction

    Discontinued [GID-IP1156]

    Interventional procedures guidance
    Discontinued

  4. Kidney transplantation (rejection) - everolimus [ID117]

    Discontinued [GID-TAG241]

    Technology appraisal guidance
    Discontinued

  5. Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

    Discontinued [GID-DT9]

    Diagnostics guidance
    Discontinued

  6. Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

    In development [GID-TAG388] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Juvenile idiopathic arthritis - adalimumab [ID385]

    Discontinued [GID-TAG400]

    Technology appraisal guidance
    Discontinued

  8. Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]

    Discontinued [GID-TAG416]

    Technology appraisal guidance
    Discontinued

  9. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development [GID-TAG406] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma

    Discontinued [GID-TA10970]

    Technology appraisal guidance
    Discontinued

  11. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued [GID-TAG401]

    Technology appraisal guidance
    Discontinued

  12. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued [GID-TAG391]

    Technology appraisal guidance
    Discontinued

  13. Vandetanib for the second line treatment of non-small cell lung cancer [ID46]

    Discontinued [GID-TAG405]

    Technology appraisal guidance
    Discontinued

  14. Erlotinib in combination with bevacizumab for the maintenance treatment of advanced or metastatic non-small cell lung cancer [ID44]

    Discontinued [GID-TA11206]

    Technology appraisal guidance
    Discontinued

  15. Erlotinib in combination with bevacizumab for the second line treatment of advanced or metastatic non-small cell lung cancer [ID43]

    Discontinued [GID-TA11207]

    Technology appraisal guidance
    Discontinued